One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
How I Approach Screening for Pancreatic Cancer
de la Fuente, Jaime MD1; Kastrinos, Fay MD, MPH2,3; Majumder, Shounak MD1
doi : 10.14309/ajg.0000000000001305
August 2021 - Volume 116 - Issue 8 - p 1569-1571
Controversies in Gastroparesis: Discussing the Sticky Points
Lacy, Brian E. MD, PhD1; Cangemi, David J. MD1
doi : 10.14309/ajg.0000000000001243
August 2021 - Volume 116 - Issue 8 - p 1572-1576
Gallbladder Carcinoma Accompanied by Pancreaticobiliary Maljunction With a Rare Double Common Bile Duct
Muramoto, Yuya MD1; Matsumori, Tomoaki MD1; Uza, Norimitsu MD, PhD1
doi : 10.14309/ajg.0000000000001063
August 2021 - Volume 116 - Issue 8 - p 1577
Rectal Pseudotumor Secondary to Chlamydia trachomatis: Not Everything Is what It Seems
Afecto, Edgar MDl; Fernandes, S?nia MDl; Rodrigues, Adélia MDl
doi : 10.14309/ajg.0000000000001107
August 2021 - Volume 116 - Issue 8 - p 1578
Unexpected Cause of Obscure Gastrointestinal Bleeding: Primary Small-Intestinal Angiosarcoma
Ertem, Furkan U. MD1; Hartman, Doug MD1; Dubner, Howard M. MD1
doi : 10.14309/ajg.0000000000001106
August 2021 - Volume 116 - Issue 8 - p 1579
Bleeding Colonic Worm-Like Polyps
Shiratori, Yasutoshi MD1; Fukuda, Katsuyuki MD, PhD1
doi : 10.14309/ajg.0000000000001127
August 2021 - Volume 116 - Issue 8 - p 1580
An Unusual Case of Acute Pancreatitis After Endoscopic Full-Thickness Resection of a Recurrent Nonampullary Duodenal Adenoma
Bonura, Giuliano Francesco MD1; Mandarino, Francesco Vito MD1; Ponz de Leon Pisani, Ruggero MD1; Dell’Anna, Giuseppe MD1; Napolitano, Maria MD1; Esposito, Dario PhD, MD2; Azzolini, Francesco MD2
doi : 10.14309/ajg.0000000000001168
August 2021 - Volume 116 - Issue 8 - p 1581
Anchoring Method to Prevent Migration of a Covered, Self-Expanding, Metal Stent Placed for Esophageal Perforation
Inoue, Takahiro MD1; Kanesaka, Takashi MD1,2; Yamamoto, Sachiko MD1; Tani, Yasuhiro MD1; Michida, Tomoki MD, PhD1; Ishihara, Ryu MD, PhD1
doi : 10.14309/ajg.0000000000001303
August 2021 - Volume 116 - Issue 8 - p 1582
CME Information
doi : 10.14309/ajg.0000000000001123
August 2021 - Volume 116 - Issue 8 - p 1583-1584
Continuing Medical Education Questions: August 2021
Ho, Edith Y. MD
doi : 10.14309/ajg.0000000000001372
August 2021 - Volume 116 - Issue 8 - p 1585
A microsimulation model to determine the cost-effectiveness of treat to target strategies for Crohn's disease
Continuing Medical Education Questions: August 2021
Shafi, Mehnaz A. MD, FACG
doi : 10.14309/ajg.0000000000001373
August 2021 - Volume 116 - Issue 8 - p 1586
Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options
Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options
Brenner, Darren M. MD, FACG1; Lacy, Brian E. MD, PhD, FACG2
doi : 10.14309/ajg.0000000000001266
August 2021 - Volume 116 - Issue 8 - p 1587-1600
Chronic abdominal pain is a common gastrointestinal (GI) symptom that characterizes many functional GI disorders/disorders of gut-brain interaction, including irritable bowel syndrome, functional dyspepsia, and centrally mediated abdominal pain syndrome. The symptoms of abdominal pain in these highly prevalent disorders are often treated with antispasmodic agents. Antispasmodic treatment includes a broad range of therapeutic classes with different mechanisms of action, including anticholinergic/antimuscarinic agents (inhibition of GI smooth muscle contraction), calcium channel inhibitors (inhibition of calcium transport into GI smooth muscle), and direct smooth muscle relaxants (inhibition of sodium and calcium transport). The aim of this review article was to examine the efficacy and safety of antispasmodics available in North America (e.g., alverine, dicyclomine, hyoscine, hyoscyamine, mebeverine, otilonium, pinaverium, and trimebutine) for the treatment of chronic abdominal pain in patients with common disorders of gut-brain interaction. For the agents examined, comparisons of studies are limited by inconsistencies in treatment dosing and duration, patient profiles, and diagnostic criteria employed. Furthermore, variability in study end points limits comparisons. Risk of selection, performance, detection, attrition, and reporting bias also differed among studies, and in many cases, risks were considered “unclear.” The antispasmodics evaluated in this review, which differ in geographic availability, were found to vary dramatically in efficacy and safety. Given these caveats, each agent should be considered on an individual basis, rather than prescribed based on information across the broad class of agents.
Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials
Shah, Eric D. MD, MBA1; Lacy, Brian E. MD, PhD2; Chey, William D. MD3; Chang, Lin MD4; Brenner, Darren M. MD5
doi : 10.14309/ajg.0000000000001313
August 2021 - Volume 116 - Issue 8 - p 1601-1611
Tegaserod was the first US Food and Drug Administration–approved drug for irritable bowel syndrome with constipation (IBS-C) in women and was recently reapproved for use. Recognizing that clinical trials were performed almost 20 years ago, we performed an integrated analysis on patient-reported outcomes relevant to current practice including previously unpublished data.
Abdominal Pain and Depression, Not Bowel Habits, Predict Health Care Utilization in Patients With Functional Bowel Disorders
Yu, Vanessa BA1; Ballou, Sarah PhD1; Hassan, Rifu MD1; Singh, Prashant MD; Shah, Eric MD, MBA2; Rangan, Vikram MD1; Iturrino, Johanna MD1; Nee, Judy MD1; Lembo, Anthony MD1
doi : 10.14309/ajg.0000000000001306
August 2021 - Volume 116 - Issue 8 - p 1720-1726
Patients with disorders of gut-brain interaction (DGBIs) are high users of health care. Past studies exploring predictors of utilization have lacked patient-level clinical data. The aim of the current study is to identify demographic, clinical, and psychological predictors of health care utilization in patients with irritable bowel syndrome (IBS), functional constipation (FC), and functional diarrhea (FDr).
Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study
Cardwell, Chris R. PhD1; McDowell, Ronald D. PhD1; Hughes, Carmel M. PhD2; Hicks, Bl?naid PhD1; Murchie, Peter MD, PhD3
doi : 10.14309/ajg.0000000000001310
August 2021 - Volume 116 - Issue 8 - p 1612-1619
Ranitidine has been shown to contain the carcinogen N-nitrosodimethylamine and increase urinary N-nitrosodimethylamine in humans. We investigated whether ranitidine use is associated with increased bladder cancer risk.
Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening
Sami, Sarmed S. MBBCh, PhD1; Moriarty, James P. MS2; Rosedahl, Jordan K. BS2; Borah, Bijan J. PhD2,3; Katzka, David A. MD4; Wang, Kenneth K. MD4; Kisiel, John B. MD5; Ragunath, Krish MD6; Rubenstein, Joel H. MD7,8; Iyer, Prasad G. MD, MSc4
doi : 10.14309/ajg.0000000000001336
August 2021 - Volume 116 - Issue 8 - p 1620-1631
Minimally invasive tests for Barrett's esophagus (BE) detection have raised the prospect of broader nonreflux-based testing. Cost-effectiveness studies have largely studied men aged 50 years with chronic gastroesophageal reflux disease (GERD) symptoms. We evaluated the comparative cost effectiveness of BE screening tests in GERD-based and GERD-independent testing scenarios.
Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection
Watanabe, Kenta MD1; Shimodaira, Yosuke MD, PhD1; Takahashi, So MD1; Fukuda, Sho MD, PhD1; Koizumi, Shigeto MD, PhD1; Matsuhashi, Tamotsu MD, PhD1; Iijima, Katsunori MD, PhD1
doi : 10.14309/ajg.0000000000001309
August 2021 - Volume 116 - Issue 8 - p 1632-1637
Proton pump inhibitors (PPIs) are associated with the onset of Clostridioides difficile infection (CDI). Although a new potassium-competitive acid blocker, vonoprazan, consistently shows a more potent acid inhibitory effect in comparison to PPIs, the risk of CDI in vonoprazan-treated patients relative to those treated with PPIs is unknown. In this retrospective case-control study, using a nationwide hospital-based administrative database in Japan, we investigated the association of the onset of CDI in patients treated with vonoprazan.
Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy
Liu, Julia J. MD, MSc1,2; Sloan, Meredith E. MD3; Owings, Anna H. DO3; Figgins, Erika BS4; Gauthier, Josee PhD5; Gharaibeh, Raad PhD5; Robinson, Tanya PhD3; Williams, Haley MS3; Sindel, Campbell B. MD3; Backus, Fremel MHIIM6; Ayyalasomayajula, Krishna PhD6; Parker, Adam MD3; Senitko, Michal MD7; Abraham, George E. III MD7; Claggett, Brian PhD8; Horwitz, Bruce H. MD, PhD9; Jobin, Christian PhD5; Adelman, Robert M. PhD10; Diamond, Gill PhD4; Glover, Sarah C. DO3
doi : 10.14309/ajg.0000000000001311
August 2021 - Volume 116 - Issue 8 - p 1638-1645
Proton pump inhibitor (PPI) use was recently reported to be associated with increased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and worse clinical outcomes. The underlying mechanism(s) for this association are unclear.
Identifying Gender Barriers for Colorectal Cancer Screening and Assessing the Need for a Multigender Endoscopy Team: A Prospective Multicenter Study
Khara, Harshit S. MD, FACG, FASGE1; Suthar, Darshan DO1; Bergenstock, Marika MD1; Berger, Andrea MAS2; McKee, Jessica L. DO1; Stewart, Dana DO1; Theis, Samuel R. DO1; Komar, Michael MD1; Johal, Amitpal S. MD1; Valencia Chavez, Diego R. MD3; Hale, William B. MD3; Mangla, Rakhee MD3
doi : 10.14309/ajg.0000000000001318
August 2021 - Volume 116 - Issue 8 - p 1646-1656
Gender preferences have been reported as a barrier to colorectal cancer screening, particularly among women. We aim to identify the role of patients' gender preferences for endoscopists and endoscopy team members, with the effect of age-related and regional differences.
Prediction of Hepatocellular Carcinoma by On-Therapy Response of Noninvasive Fibrosis Markers in Chronic Hepatitis B
Nam, Heechul MD1,2; Lee, Sung Won MD1,2; Kwon, Jung Hyun MD, PhD1,2; Lee, Hae Lim MD1,2; Yoo, Sun Hong MD, PhD1,2; Kim, Hee Yeon MD, PhD1,2; Song, Do Seon MD, PhD1,2; Sung, Pil Soo MD, PhD1,2; Chang, U Im MD, PhD1,2; Kim, Chang Wook MD, PhD1,2; Nam, Soon Woo MD, PhD1,2; Bae, Si Hyun MD, PhD1,2; Choi, Jong Young MD, PhD1,2; Yoon, Seung Kew MD, PhD1,2; Yang, Jin Mo MD, PhD1,2; Han, Nam Ik MD, PhD1,2; Jang, Jeong Won MD, PhD1,2
doi : 10.14309/ajg.0000000000001219
August 2021 - Volume 116 - Issue 8 - p 1657-1666
Antiviral therapy improves hepatic fibrosis and reduces hepatocellular carcinoma (HCC) incidence. This study aimed to evaluate whether on-therapy changes in scores for fibrosis index based on 4 factors and aspartate aminotransferase-to-platelet ratio index are associated with HCC development and establish an HCC risk score model incorporating noninvasive fibrosis marker (NFM) response.
Red Meat Consumption and Risk of Nonalcoholic Fatty Liver Disease in a Population With Low Meat Consumption: The Golestan Cohort Study
Hashemian, Maryam MD, PhD1,2; Merat, Shahin MD3; Poustchi, Hossein MD, PhD3; Jafari, Elham MD, MPH3; Radmard, Amir-Reza MD4; Kamangar, Farin MD, PhD1,5; Freedman, Neal PhD6; Hekmatdoost, Azita MD, PhD7; Sheikh, Mahdi MD, PhD1,8; Boffetta, Paolo MD, PhD9,10; Sinha, Rashmi PhD6; Dawsey, Sanford M. MD6; Abnet, Christian C. PhD, MPH6; Malekzadeh, Reza MD1; Etemadi, Arash MD, PhD1,6
doi : 10.14309/ajg.0000000000001229
August 2021 - Volume 116 - Issue 8 - p 1667-1675
Nonalcoholic fatty liver disease (NAFLD), as the most common liver disease in the world, can range from simple steatosis to steatohepatitis. We evaluated the association between meat consumption and risk of NAFLD in the Golestan Cohort Study (GCS).
Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B
Ji, Dong MD, PhD1; Chen, Yan MD1; Shang, Qinghua MD2; Liu, Huabao MD3; Tan, Lin MD4; Wang, Jing MD5; Chen, Yongping MD6; Li, Qin MD7; Long, Qinghua MD8; Song, Laicheng MD9; Jiang, Li MD10; Xiao, Guangming MD11; Yu, Zujiang MD12; Chen, Liang MD13; Hu, Xiaoyu MD14; Wang, Xiaodong MD6; Chen, Da MD7; Li, Zhiqin MD12; Dong, Zheng MD1; Chen, Guofeng MD1; Yang, Yongping MD1
doi : 10.14309/ajg.0000000000001239
August 2021 - Volume 116 - Issue 8 - p 1676-1685
Little reliable evidence has been reported regarding usefulness of liver stiffness measurement (LSM) for monitoring the hepatic fibrosis changes during treatment. We aimed to assess the association between changes in LSM and histological outcomes in patients with chronic hepatitis B.
Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B
Khalili, Mandana MD1; Kleiner, David E. MD2; King, Wendy C. PhD3; Sterling, Richard K. MD, MSc4; Ghany, Marc G. MD2; Chung, Raymond T. MD5; Bhan, Atul K. MD5,6; Rosenthal, Philip MD1; Lisker-Melman, Mauricio MD7; Ramachandran, Rageshree MD1; Lok, Anna S. MD8; ; and the Hepatitis B Research Network (HBRN)
doi : 10.14309/ajg.0000000000001257
August 2021 - Volume 116 - Issue 8 - p 1686-1697
Fatty liver disease (FLD) influences liver disease progression and liver cancer risk. We investigated the impact of FLD on liver disease severity in a large North American cohort with chronic hepatitis B virus (HBV).
Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation
Kawaguchi, Yoshikuni MD, PhD1,*; Hasegawa, Kiyoshi MD, PhD1,*; Hagiwara, Yasuhiro PhD2,*; De Bellis, Mario MD3; Famularo, Simone MD4,5; Panettieri, Elena MD6; Matsuyama, Yutaka PhD2,*; Tateishi, Ryosuke MD, PhD7,*; Ichikawa, Tomoaki MD, PhD8,*; Kokudo, Takashi MD, PhD1,*; Izumi, Namiki MD, PhD9,*; Kubo, Shoji MD, PhD10,*; Sakamoto, Michiie MD, PhD11,*; Shiina, Shuichiro MD, PhD12,*; Takayama, Tadatoshi MD, PhD13,*; Nakashima, Osamu MD, PhD14,*; Murakami, Takamichi MD, PhD15,*; Vauthey, Jean-Nicolas MD16; Giuliante, Felice MD6; De Carlis, Luciano MD4,17; Romano, Fabrizio MD4,5; Ruzzenente, Andrea MD, PhD3; Guglielmi, Alfredo MD3; Kudo, Masatoshi MD, PhD18,*; Kokudo, Norihiro MD, PhD19,*
doi : 10.14309/ajg.0000000000001256
August 2021 - Volume 116 - Issue 8 - p 1698-1708
Most studies predicting survival after resection, transarterial chemoembolization (TACE), and ablation analyzed diameter and number of hepatocellular carcinomas (HCCs) as dichotomous variables, resulting in an underestimation of risk variation. We aimed to develop and validate a new prognostic model for patients with HCC using largest diameter and number of HCCs as continuous variables.
A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease
Dulai, Parambir S. MD1; Jairath, Vipul MD, PhD2; Narula, Neeraj MD3; Wong, Emily BS3; Kochhar, Gursimran S. MD4; Colombel, Jean-Frederic MD5; Sandborn, William J. MD1
doi : 10.14309/ajg.0000000000001263
August 2021 - Volume 116 - Issue 8 - p 1709-1719
Cost-effectiveness of biomarker- vs endoscopy-based treat-to-target monitoring in Crohn's disease (CD) is unknown.
Esophageal Mucosa Innervation in Children With Nonerosive Reflux Disease
Nikaki, Kornilia MD1; Lee, Chung BSc, MSc1; Ustaoglu, Ahsen BSc, MRes1; Alessandrella, Annalisa MD2; Staiano, Annamaria MD2; Woodland, Philip MD, PhD1; Sifrim, Daniel MD, PhD1
doi : 10.14309/ajg.0000000000001286
August 2021 - Volume 116 - Issue 8 - p 1727-1729
Esophageal mucosa innervation in adults with nonerosive reflux disease (NERD) is more superficial compared with healthy volunteers. We delineated the esophageal mucosal innervation in pediatric NERD and controls.
Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists
Ozanne, Elissa M. PhD1; Silver, Elisabeth R. BS2; Saini, Sameer D. MD3,4,5; Rubenstein, Joel H. MD, MSc3,6; Lansdorp-Vogelaar, Iris PhD7; Bowers, Nicole BA4; Tan, Sarah Xinhui BS2; Inadomi, John M. MD8; Hur, Chin MD, MPH2,9,10
doi : 10.14309/ajg.0000000000001323
August 2021 - Volume 116 - Issue 8 - p 1730-1733
Regular endoscopic surveillance is the gold standard Barrett's esophagus (BE) surveillance, yet harms of surveillance for some patients may outweigh the benefits. We sought to characterize physicians' BE surveillance cessation recommendations.
Characteristics and Outcomes of Children With Cystic Fibrosis Hospitalized With Cirrhosis in the United States
Thornton, Christina MD, PhD1; Somayaji, Ranjani MD, MPH1,2,3; Parkins, Michael MD, MSc1,2; Swain, Mark G. MD1; Ramos, Kathleen J. MD, MSc4; Goss, Christopher H. MD, MSc4; Shaheen, Abdel A. MD, MSc1,2,3
doi : 10.14309/ajg.0000000000001275
August 2021 - Volume 116 - Issue 8 - p 1734-1737
To describe the characteristics and outcomes of children with cystic fibrosis (CF) hospitalized with cirrhosis in the United States.
Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada
Konstantelos, Natalia BSc1,2; Shakeri, Ahmad MSc1; McCormack, Daniel MSc3; Feld, Jordan J. MD, MPH4,5; Gomes, Tara PhD2,3,6; Tadrous, Mina PharmD, PhD1,2,3
doi : 10.14309/ajg.0000000000001287
August 2021 - Volume 116 - Issue 8 - p 1738-1740
Direct-acting antivirals (DAAs) are curative treatments for hepatitis C. However, initiation of these treatments requires adequate healthcare access. Coronavirus 2019 (COVID-19) resulted in restrictions to healthcare services in March 2020. We examined the impact of COVID-19 on the number of individuals dispensed DAAs.
Mortality in Patients With Genetic and Environmental Risk of Liver Disease
Schneider, Carolin V. MD1,2; Fromme, Malin2; Schneider, Kai Markus MD, PhD2,3; Bruns, Tony MD2; Strnad, Pavel MD2
doi : 10.14309/ajg.0000000000001326
August 2021 - Volume 116 - Issue 8 - p 1741-1745
The increasing liver-related mortality calls for hepatic surveillance programs. To design them, factors selectively increasing liver-related vs overall mortality need to be identified.
Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease
Botwin, Gregory J. BS1,2; Li, Dalin PhD1,2; Figueiredo, Jane PhD2,3; Cheng, Susan MD, MMSc, MPH4; Braun, Jonathan MD, PhD1,2,5; McGovern, Dermot P. B. MD, PhD1,2,5; Melmed, Gil Y. MD, MS, FACG, AGAF1,2
doi : 10.14309/ajg.0000000000001342
August 2021 - Volume 116 - Issue 8 - p 1746-1751
Patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from severe acute respiratory syndrome coronavirus-2 messenger RNA vaccine trials.
Decreasing Stigmatization of Persons With Higher Weights: When Words Count
Nassani, Najib MD, MSc1; El-Khoury, Rita MD2,3
doi : 10.14309/ajg.0000000000001249
August 2021 - Volume 116 - Issue 8 - p 1752
Ending Obesity Stigma and Discrimination: Starting From Healthcare Professionals
Zhang, Wen RN1; Mahawar, Kamal MD2; Parmar, Chetan MD3,4; Chen, Weiju RN1; Wang, Cunchuan MD, PhD5,6; Yang, Wah MD5,6,7,8, on behalf of Global Bariatric Research Collaborative
doi : 10.14309/ajg.0000000000001269
August 2021 - Volume 116 - Issue 8 - p 1753
Response to Nassani and El-Khoury
Bhalla, Sean MD1; Schulman, Allison R. MD, MPH1,2
doi : 10.14309/ajg.0000000000001307
August 2021 - Volume 116 - Issue 8 - p 1753-1754
Bariatric Surgery and Esophageal Function: An Eternal Impasse?
Gualtieri, Giorgia MD1; Savarino, Edoardo MD, PhD2; Barberio, Brigida MD2; Tolone, Salvatore MD, PhD, FACS1
doi : 10.14309/ajg.0000000000001276
August 2021 - Volume 116 - Issue 8 - p 1754-1755
Response to Gualtieri et al.
Ravi, K. MD1; Abu Dayyeh, B.K. MD, MPH1; Katzka, D.A. MD1
doi : 10.14309/ajg.0000000000001291
August 2021 - Volume 116 - Issue 8 - p 1755-1756
Avoiding Beta Blockers in Patients of Hepatitis C Virus-Related Compensated Cirrhosis With Clinically Significant Portal Hypertension After Cure With Antivirals: Are We There Yet?
Sharma, Sanchit MD1; Saraya, Anoop MD, DM, DNB1
doi : 10.14309/ajg.0000000000001267
August 2021 - Volume 116 - Issue 8 - p 1756
Response to Sharma and Saraya
Tosetti, Giulia MD1; Primignani, Massimo MD1
doi : 10.14309/ajg.0000000000001290
August 2021 - Volume 116 - Issue 8 - p 1756-1757
Esophageal Squamous Cell Carcinoma: Time to Predict the Risk?
Lai, Rui-Ping BMed, MPH1
doi : 10.14309/ajg.0000000000001293
August 2021 - Volume 116 - Issue 8 - p 1757-1758
Response to Lai
Wang, Qiao-Li MD, PhD1; Lagergren, Jesper MD, PhD1
doi : 10.14309/ajg.0000000000001312
August 2021 - Volume 116 - Issue 8 - p 1758
Eosinophilic Esophagitis and Achalasia: Are We Putting All the Pieces Together?
Ghisa, Matteo MD1,2; Barberio, Brigida MD1; Buda, Andrea MD, PhD2; Savarino, Edoardo MD, PhD1
doi : 10.14309/ajg.0000000000001268
August 2021 - Volume 116 - Issue 8 - p 1759
Response to Ghisa et al.
King, Dominic MBChB1; Trudgill, Nigel MD1
doi : 10.14309/ajg.0000000000001327
August 2021 - Volume 116 - Issue 8 - p 1759
Therapeutic Response to Adalimumab in a Case of Steroid-Dependent Segmental Colitis Associated With Diverticulosis
Tursi, Antonio MD1,2; Nenna, Rosanna MD3; Danese, Silvio MD, PhD4,5
doi : 10.14309/ajg.0000000000001226
August 2021 - Volume 116 - Issue 8 - p 1760-1761
A Rare Case of Locally Advanced Squamous Cell Carcinoma of the Esophagogastric Junction With Submucosal Progression and Long-Term Survival
Carboni, Fabio MD, PhD, MMeD1; Federici, Orietta MD1; Zazza, Settimio MD1; Corona, Francesco MD1; Valle, Mario MD, FACS1
doi : 10.14309/ajg.0000000000001250
August 2021 - Volume 116 - Issue 8 - p 1762
Deglutition Syncope After Variceal Band Ligation
Taguchi, Yumiko V. PhD1; Snyder, Diana L. MD2; Shah, Jay B. MD3; Dickson, Rolland C. MD2
doi : 10.14309/ajg.0000000000001248
August 2021 - Volume 116 - Issue 8 - p 1763
Go With the Flow: Alternative Terminology in Relational Anatomy
Thomas, Maria C. BS1; Chang, Enchi K. BS1; Petersen, Bret T. MD2; Bazerbachi, Fateh MD1,3
doi : 10.14309/ajg.0000000000001252
August 2021 - Volume 116 - Issue 8 - p 1764
Cronkhite-Canada Syndrome: A Rare COVID-19 Mimicker
Yoshimoto, Takaaki MD1; Okamoto, Takeshi MD1; Fukuda, Katsuyuki MD, PhD1
doi : 10.14309/ajg.0000000000001254
August 2021 - Volume 116 - Issue 8 - p 1765
Hypocrisy and Tragedy of the Commons
Sonnenberg, Amnon MD, MSc1,2
doi : 10.14309/ajg.0000000000001289
August 2021 - Volume 116 - Issue 8 - p 1766-1767
2021 GI FELLOWSHIP TRAINING PROGRAMS
doi : 10.14309/ajg.0000000000001387
August 2021 - Volume 116 - Issue 8 - p 1768-1812
Calendar of Courses, Symposiums and Conferences
doi : 10.14309/ajg.0000000000001388
August 2021 - Volume 116 - Issue 8 - p 1813
